Global Cell-Free DNA Testing Market was valued at US$ 9.58 Bn in 2023 and is expected to reach US$ 48.03 Bn by 2030, at a CAGR of 25.90% during a forecast period Cell-free DNA (cfDNA) is also called NIPT. The non-invasive prenatal test is a new technology being used to assess the risk of a pregnant woman's and taking a sample of blood from the vein rather than inserting a needle into the uterus similar to amniocentesis. The cell-free DNA testing is used in many fields such as gynecology, oncology, and transplantation to identify mutations in cancer patients and identify various chromosomal abnormalities in the fetus, to know the gender of the fetus. Increasing healthcare expenditure, and growing healthcare awareness are the key reasons driving the cell-free DNA market.To know about the Research Methodology:-Request Free Sample Report
Cell-Free DNA Testing Market Dynamics
Unhealthy Lifestyles and Prenatal Concerns Drive Cell-Free DNA Testing Market Growth The risk of chronic diseases owing to unhealthy lifestyles and food habits is expected to drive the growth of the cell-free DNA testing market. Health-damaging lifestyle actions such as the increased use of tobacco & alcohol, lack of physical activity, poor eating habits, or heavy consumption of fast foods are the major factors responsible for chronic diseases. Inherited abnormalities among infants are also increasing across the globe because of advanced maternal age. Advances in molecular pathogenesis, growing parasitic infection, the surge in prenatal complications, and alertness for prenatal testing offer potential growth opportunities for market expansion. However, problems like high test costs, lack of skilled healthcare professionals, and ethical issues related to genetic testing obstruct the growth of the cfDNA testing market. Rising Demand for NIPT Drives Growth in Cell-Free Fetal DNA Testing Market for Accurate Aneuploidy Screening Growing alertness in the people and the requirement of safe & low-risk obstetric procedures for prenatal testing. The growth of the cell-free fetal DNA testing market is mainly expected to exact and effective results for aneuploidy screening. NIPT is a screening test that offers information regarding only Down syndrome trisomy 21, trisomy 18, and trisomy 13. A trisomy occurs when there is an extra copy of a particular chromosome in every single cell. Down syndrome is generally caused by an error in cell division called “nondisjunction.” It is caused when abnormal cell division results in extra genetic material from chromosome 21 High Costs Impede Widespread Adoption of Cell-Free DNA Testing High test costs significantly hinder the widespread adoption of cfDNA testing. The advanced technology and specialized equipment necessary for accurate analysis drive up expenses, making these tests less accessible to a broader population. Despite the potential benefits of early disease detection and prenatal screening, the financial burden remains a major obstacle. This limits the utilization of cfDNA testing, particularly in lower-income regions and among individuals without sufficient health insurance coverage. Addressing cost-related challenges is crucial for broader implementation and maximizing the public health benefits of cfDNA testing.Cell-Free DNA Testing Market Segment Analysis
Oncology Segment Leading the Cell-Free DNA Testing Market According to MMR analysis, The oncology segment has dominated the cell-free DNA (cfDNA) testing industry and is expected to grow in the forecast period. Owing to its critical role in cancer diagnosis, monitoring, and treatment. cfDNA testing, particularly through circulating tumor DNA (ctDNA), offers non-invasive methods to detect and analyze tumor-derived genetic material in the bloodstream. This allows for early cancer detection, real-time tumor dynamics monitoring, and treatment efficacy assessment.• For example, the Guardant360 test, a leading ctDNA test, is used to identify actionable genetic mutations in cancer patients, guiding personalized treatment strategies.
• The use of cfDNA testing in liquid biopsies for lung cancer patients enables the detection of EGFR mutations without the need for invasive tissue biopsies.
Cell-Free DNA Testing Market Regional Analysis
According to MMR analysis, North America is expected to hold the largest market share during the forecast period followed by Europe and Asia-Pacific. Owing to the rising mandate for a non-invasive test for cancer screening and clinical & research studies. An increasing prevalence of diseases related to lifestyle change and government initiatives in establishing innovative technologies and demand for sophisticated medical services is estimated to grow in significant rate in the Asia-Pacific region. Asia-Pacific (APAC) emerges as the fastest-growing region in the cfDNA testing market. The region's burgeoning population, increasing healthcare expenditure, and rising awareness about advanced diagnostic technologies contribute to this growth. Rapid urbanization and lifestyle changes are fueling the prevalence of chronic diseases, driving the demand for early detection and personalized treatment options offered by cfDNA testing. Countries like China, India, and Japan are witnessing significant investments in healthcare infrastructure and research, fostering the adoption of cfDNA testing. Moreover, supportive government initiatives and collaborations with global healthcare firms further propel market expansion in the region. APAC's dynamic healthcare landscape and growing emphasis on precision medicine make it the fastest-growing region in the cfDNA testing market, presenting lucrative opportunities for industry players.Cell-Free DNA Testing Market Competitive Analysis
Key player operating in the global cell-free DNA testing market are Berry Genomics Co. Ltd, Bgi, Biocartis, Biocept, Inc., Biodesix, Inc., Boreal Genomics, Caredx, Inc., Chronix Biomedical, Circulogene Theranostics, Counsyl, Inc., Cynvenio Biosystems Inc, Exact Sciences, Foundation Medicine, Gatc Biotech, Guardant Health, Inc, Illumina, Inc., Inivata Limited, Laboratory Corp. Of America Holdings, Lifecodexx Ag, Molecular Md, Multiplicom Nv, Natera, Inc., Neo New Oncology Ag, Neogenomics Laboratories, Pathway Genomics, Personal Genome Diagnostics, Predicine Holdings Ltd., Premaitha Health Plc, Prenatalis, Quest Diagnostics, Roche Holdings Ag, Sequenom, Inc., Sysmex Inostics, Tai Diagnostics, Inc., The Chinese University Of Hong Kong, Transgenomic, Inc., and Trovagene, Inc.Cell-Free DNA Testing Market Scope: Inquire before buying
Global Cell-Free DNA Testing Market Report Coverage Details Base Year: 2023 Forecast Period: 2024-2030 Historical Data: 2018 to 2022 Market Size in 2023: US $ 9.58 Bn. Forecast Period 2024 to 2030 CAGR: 25.9% Market Size in 2030: US $ 48.03 Bn. Segments Covered: by Product Donor-Derived Cell-Free DNA Circulating Cell-Free Tumor DNA Cell-Free Fetal DNA by Platforms NGS rPCR & multiplexed PCR qPCR & dPCR Other platform by Application Oncology NIPT (Non-Invasive Prenatal Test) Gynecology Transplantation Other Disease Conditions Cell-Free DNA Testing Market, by Region:
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) North America (United States, Canada and Mexico) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Key Player:
1. Berry Genomics Co. Ltd 2. Bgi 3. Biocartis 4. Biocept, Inc. 5. Biodesix, Inc. 6. Boreal Genomics 7. Caredx, Inc. 8. Chronix Biomedical 9. Circulogene Theranostics 10. Counsyl, Inc. 11. Cynvenio Biosystems Inc 12. Exact Sciences 13. Foundation Medicine 14. Gatc Biotech 15. Guardant Health, Inc 16. Illumina, Inc. 17. Inivata Limited 18. Laboratory Corp. Of America Holdings 19. Lifecodexx Ag 20. Molecular Md 21. Multiplicom Nv 22. Natera, Inc. 23. Neo New Oncology Ag 24. Neogenomics Laboratories 25. Pathway Genomics 26. Personal Genome Diagnostics 27. Predicine Holdings Ltd. 28. Premaitha Health Plc 29. Prenatalis 30. Quest Diagnostics 31. Roche Holdings Ag 32. Sequenom, Inc. 33. Sysmex Inostics 34. Tai Diagnostics, Inc. 35. The Chinese University Of Hong Kong 36. Transgenomic, Inc. 37. Trovagene, Inc. Frequently Asked Questions: 1. Which region has the largest share in Global Cell-free DNA testing Market? Ans: Asia Pacific region holds the highest share in 2023. 2. What is the growth rate of Global Cell-free DNA testing Market? Ans: The Global market is growing at a CAGR of 25.9% during forecasting period 2024-2030. 3. What is scope of the Global Cell-free DNA testing market report? Ans: Global market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Cell-free DNA testing market? Ans: The important key players in the Global market are – Berry Genomics Co. Ltd, Bgi, Biocartis, Biocept, Inc., Biodesix, Inc., Boreal Genomics, Caredx, Inc., Chronix Biomedical, Circulogene Theranostics, Counsyl, Inc., Cynvenio Biosystems Inc, Exact Sciences, Foundation Medicine, Gatc Biotech, Guardant Health, Inc, Illumina, Inc., Inivata Limited, Laboratory Corp. Of America Holdings, Lifecodexx Ag, Molecular Md, Multiplicom Nv, Natera, Inc., Neo New Oncology Ag, Neogenomics Laboratories, Pathway Genomics, Personal Genome Diagnostics, Predicine Holdings Ltd., Premaitha Health Plc, Prenatalis, Quest Diagnostics, Roche Holdings Ag, Sequenom, Inc., Sysmex Inostics, Tai Diagnostics, Inc., The Chinese University Of Hong Kong, Transgenomic, Inc., Trovagene, Inc. 5. What is the study period of this market? Ans: The Global market is studied from 2023 to 2030.
Global Cell-Free DNA Testing Market
1. Preface 1.1. Research Objectives 1.2. Report Scope and Market Segmentation 2. Assumptions and Research Methodology 2.1. Abbreviations 3. Executive Summary 3.1. Global Cell-Free DNA Testing Market Size, by Market Value (US$ Mn) and Market 4. Market Overview 4.1. Introduction 4.2. Market Dynamics 4.3. Drivers and Restraints Snapshot Analysis 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.3.4. Porter’s Analysis 4.3.5. Value Chain Analysis 4.3.6. SWOT Analysis 4.3.7. Key Trends in Global Cell-Free DNA Testing Market 5. Global Cell-Free DNA Testing Market Analysis and Forecast 5.1. Global Cell-Free DNA Testing Market Size& Y-o-Y Growth Analysis 5.1.1. North America 5.1.2. Europe 5.1.3. Asia Pacific 5.1.4. Middle East & Africa 5.1.5. South America 6. Global Cell-Free DNA Testing Market Analysis and Forecast, By Products 6.1. Introduction and Definition 6.2. Global Cell-Free DNA Testing Market Value Share Analysis, By Products 6.3. Global Cell-Free DNA Testing Market Size (US$ Mn) Forecast, By Products 6.4. Global Cell-Free DNA Testing Market Analysis, By Products 6.5. Global Cell-Free DNA Testing Market Attractiveness Analysis, By Products 6.6. Key Trends 6.6.1. Key Developments 7. Global Cell-Free DNA Testing Market Analysis and Forecast, By Platforms 7.1. Introduction and Definition 7.2. Global Cell-Free DNA Testing Market Value Share Analysis, By Platforms 7.3. Global Cell-Free DNA Testing Market Size (US$ Mn) Forecast, By Platforms 7.4. Global Cell-Free DNA Testing Market Analysis, By Platforms 7.5. Global Cell-Free DNA Testing Market Attractiveness Analysis, By Platforms 7.6. Key Trends 7.6.1. Key Developments 8. Global Cell-Free DNA Testing Market Analysis and Forecast, By Applications 8.1. Introduction and Definition 8.2. Global Cell-Free DNA Testing Market Value Share Analysis, By Applications 8.3. Global Cell-Free DNA Testing Market Size (US$ Mn) Forecast, By Applications 8.4. Global Cell-Free DNA Testing Market Analysis, By Applications 8.5. Global Cell-Free DNA Testing Market Attractiveness Analysis, By Applications 8.6. Key Trends 8.6.1. Key Developments 9. Global Cell-Free DNA Testing Market Analysis, by Region 9.1. Global Cell-Free DNA Testing Market Value Share Analysis, by Region 9.2. Global Cell-Free DNA Testing Market Size (US$ Mn) Forecast, by Region 9.3. Global Cell-Free DNA Testing Market Attractiveness Analysis, by Region 9.4. Key Trends 9.4.1. Key Developments 10. North America Cell-Free DNA Testing Market Analysis 10.1. North America Cell-Free DNA Testing Market Overview 10.2. North America Cell-Free DNA Testing Market Value Share Analysis, By Products 10.3. North America Cell-Free DNA Testing Market Forecast, By Products 10.3.1. Donor-Derived Cell-Free DNA (DdcfDNA) 10.3.2. Circulating Cell-Free Tumor DNA (CtDNA) 10.3.3. Cell-Free Fetal DNA 10.4. North America Cell-Free DNA Testing Market Value Share Analysis, By Platforms 10.5. North America Cell-Free DNA Testing Market Forecast, By Platforms 10.5.1. NGS 10.5.2. RPCR & multiplexed PCR 10.5.3. QPCR & dPCR 10.5.4. Other platform 10.6. North America Cell-Free DNA Testing Market Value Share Analysis, By Applications 10.7. North America Cell-Free DNA Testing Market Forecast, By Applications 10.7.1. Oncology 10.7.2. NIPT 10.7.3. Gynecology 10.7.4. Transplantation 10.7.5. Other Disease Conditions 10.8. North America Cell-Free DNA Testing Market Value Share Analysis, by Country 10.9. North America Cell-Free DNA Testing Market Forecast, by Country 10.9.1. U.S. 10.9.2. Canada 10.10. North America Cell-Free DNA Testing Market Analysis, by Country 10.11. U.S. Cell-Free DNA Testing Market Forecast, By Products 10.11.1. Donor-Derived Cell-Free DNA (DdcfDNA) 10.11.2. Circulating Cell-Free Tumor DNA (CtDNA) 10.11.3. Cell-Free Fetal DNA 10.12. U.S. Cell-Free DNA Testing Market Forecast, By Platforms 10.12.1. NGS 10.12.2. RPCR & multiplexed PCR 10.12.3. QPCR & dPCR 10.12.4. Other platform 10.13. U.S. Cell-Free DNA Testing Market Forecast, By Applications 10.13.1. Oncology 10.13.2. NIPT 10.13.3. Gynecology 10.13.4. Transplantation 10.13.5. Other Disease Conditions 10.14. Canada Cell-Free DNA Testing Market Forecast, By Products 10.14.1. Donor-Derived Cell-Free DNA (DdcfDNA) 10.14.2. Circulating Cell-Free Tumor DNA (CtDNA) 10.14.3. Cell-Free Fetal DNA 10.15. Canada Cell-Free DNA Testing Market Forecast, By Platforms 10.15.1. NGS 10.15.2. RPCR & multiplexed PCR 10.15.3. QPCR & dPCR 10.15.4. Other platform 10.16. Canada Cell-Free DNA Testing Market Forecast, By Applications 10.16.1. Oncology 10.16.2. NIPT 10.16.3. Gynecology 10.16.4. Transplantation 10.16.5. Other Disease Conditions 10.17. North America Cell-Free DNA Testing Market Attractiveness Analysis 10.17.1. By Products 10.17.2. By Platforms 10.17.3. By Applications 10.18. PEST Analysis 10.19. Key Trends 10.19.1. Key Developments 11. Europe Cell-Free DNA Testing Market Analysis 11.1. Europe Cell-Free DNA Testing Market Overview 11.2. Europe Cell-Free DNA Testing Market Value Share Analysis, By Products 11.3. Europe Cell-Free DNA Testing Market Forecast, By Products 11.3.1. Donor-Derived Cell-Free DNA (DdcfDNA) 11.3.2. Circulating Cell-Free Tumor DNA (CtDNA) 11.3.3. Cell-Free Fetal DNA 11.4. Europe Cell-Free DNA Testing Market Value Share Analysis, By Platforms 11.5. Europe Cell-Free DNA Testing Market Forecast, By Platforms 11.5.1. NGS 11.5.2. RPCR & multiplexed PCR 11.5.3. QPCR & dPCR 11.5.4. Other platform 11.6. Europe Cell-Free DNA Testing Market Value Share Analysis, By Applications 11.7. Europe Cell-Free DNA Testing Market Forecast, By Applications 11.7.1. Oncology 11.7.2. NIPT 11.7.3. Gynecology 11.7.4. Transplantation 11.7.5. Other Disease Conditions 11.8. Europe Cell-Free DNA Testing Market Value Share Analysis, by Country 11.9. Europe Cell-Free DNA Testing Market Forecast, by Country 11.9.1. Germany 11.9.2. U.K. 11.9.3. France 11.9.4. Italy 11.9.5. Spain 11.9.6. Rest of Europe 11.10. Europe Cell-Free DNA Testing Market Analysis, by Country/ Sub-region 11.11. Germany Cell-Free DNA Testing Market Forecast, By Products 11.11.1. Donor-Derived Cell-Free DNA (DdcfDNA) 11.11.2. Circulating Cell-Free Tumor DNA (CtDNA) 11.11.3. Cell-Free Fetal DNA 11.12. Germany Cell-Free DNA Testing Market Forecast, By Platforms 11.12.1. NGS 11.12.2. RPCR & multiplexed PCR 11.12.3. QPCR & dPCR 11.12.4. Other platform 11.13. Germany Cell-Free DNA Testing Market Forecast, By Applications 11.13.1. Oncology 11.13.2. NIPT 11.13.3. Gynecology 11.13.4. Transplantation 11.13.5. Other Disease Conditions 11.14. U.K. Cell-Free DNA Testing Market Forecast, By Products 11.14.1. Donor-Derived Cell-Free DNA (DdcfDNA) 11.14.2. Circulating Cell-Free Tumor DNA (CtDNA) 11.14.3. Cell-Free Fetal DNA 11.15. U.K. Cell-Free DNA Testing Market Forecast, By Platforms 11.15.1. NGS 11.15.2. RPCR & multiplexed PCR 11.15.3. QPCR & dPCR 11.15.4. Other platform 11.16. U.K. Cell-Free DNA Testing Market Forecast, By Applications 11.16.1. Oncology 11.16.2. NIPT 11.16.3. Gynecology 11.16.4. Transplantation 11.16.5. Other Disease Conditions 11.17. France Cell-Free DNA Testing Market Forecast, By Products 11.17.1. Donor-Derived Cell-Free DNA (DdcfDNA) 11.17.2. Circulating Cell-Free Tumor DNA (CtDNA) 11.17.3. Cell-Free Fetal DNA 11.18. France Cell-Free DNA Testing Market Forecast, By Platforms 11.18.1. NGS 11.18.2. RPCR & multiplexed PCR 11.18.3. QPCR & dPCR 11.18.4. Other platform 11.19. France Cell-Free DNA Testing Market Forecast, By Applications 11.19.1. Oncology 11.19.2. NIPT 11.19.3. Gynecology 11.19.4. Transplantation 11.19.5. Other Disease Conditions 11.20. Italy Cell-Free DNA Testing Market Forecast, By Products 11.20.1. Donor-Derived Cell-Free DNA (DdcfDNA) 11.20.2. Circulating Cell-Free Tumor DNA (CtDNA) 11.20.3. Cell-Free Fetal DNA 11.21. Italy Cell-Free DNA Testing Market Forecast, By Platforms 11.21.1. NGS 11.21.2. RPCR & multiplexed PCR 11.21.3. QPCR & dPCR 11.21.4. Other platform 11.22. Italy Cell-Free DNA Testing Market Forecast, By Applications 11.22.1. Oncology 11.22.2. NIPT 11.22.3. Gynecology 11.22.4. Transplantation 11.22.5. Other Disease Conditions 11.23. Spain Cell-Free DNA Testing Market Forecast, By Products 11.23.1. Donor-Derived Cell-Free DNA (DdcfDNA) 11.23.2. Circulating Cell-Free Tumor DNA (CtDNA) 11.23.3. Cell-Free Fetal DNA 11.24. Spain Cell-Free DNA Testing Market Forecast, By Platforms 11.24.1. NGS 11.24.2. RPCR & multiplexed PCR 11.24.3. QPCR & dPCR 11.24.4. Other platform 11.25. Spain Cell-Free DNA Testing Market Forecast, By Applications 11.25.1. Oncology 11.25.2. NIPT 11.25.3. Gynecology 11.25.4. Transplantation 11.25.5. Other Disease Conditions 11.26. Rest of Europe Cell-Free DNA Testing Market Forecast, By Products 11.26.1. Donor-Derived Cell-Free DNA (DdcfDNA) 11.26.2. Circulating Cell-Free Tumor DNA (CtDNA) 11.26.3. Cell-Free Fetal DNA 11.27. Rest of Europe Cell-Free DNA Testing Market Forecast, By Platforms 11.27.1. NGS 11.27.2. RPCR & multiplexed PCR 11.27.3. QPCR & dPCR 11.27.4. Other platform 11.28. Rest of Europe Cell-Free DNA Testing Market Forecast, By Applications 11.28.1. Oncology 11.28.2. NIPT 11.28.3. Gynecology 11.28.4. Transplantation 11.28.5. Other Disease Conditions 11.29. Europe Cell-Free DNA Testing Market Attractiveness Analysis 11.29.1. By Products 11.29.2. By Platforms 11.29.3. By Applications 11.30. PEST Analysis 11.31. Key Trends 11.31.1. Key Developments 12. Asia Pacific Cell-Free DNA Testing Market Analysis 12.1. Asia Pacific Cell-Free DNA Testing Market Overview 12.2. Asia Pacific Cell-Free DNA Testing Market Value Share Analysis, By Products 12.3. Asia Pacific Cell-Free DNA Testing Market Forecast, By Products 12.3.1. Donor-Derived Cell-Free DNA (DdcfDNA) 12.3.2. Circulating Cell-Free Tumor DNA (CtDNA) 12.3.3. Cell-Free Fetal DNA 12.4. Asia Pacific Cell-Free DNA Testing Market Value Share Analysis, By Platforms 12.5. Asia Pacific Cell-Free DNA Testing Market Forecast, By Platforms 12.5.1. NGS 12.5.2. RPCR & multiplexed PCR 12.5.3. QPCR & dPCR 12.5.4. Other platform 12.6. Asia Pacific Cell-Free DNA Testing Market Value Share Analysis, By Applications 12.7. Asia Pacific Cell-Free DNA Testing Market Forecast, By Applications 12.7.1. Oncology 12.7.2. NIPT 12.7.3. Gynecology 12.7.4. Transplantation 12.7.5. Other Disease Conditions 12.8. Asia Pacific Cell-Free DNA Testing Market Value Share Analysis, by Country 12.9. Asia Pacific Cell-Free DNA Testing Market Forecast, by Country 12.9.1. China 12.9.2. India 12.9.3. Japan 12.9.4. ASEAN 12.9.5. Rest of Asia Pacific 12.10. Asia Pacific Cell-Free DNA Testing Market Analysis, by Country/ Sub-region 12.11. China Cell-Free DNA Testing Market Forecast, By Products 12.11.1. Donor-Derived Cell-Free DNA (DdcfDNA) 12.11.2. Circulating Cell-Free Tumor DNA (CtDNA) 12.11.3. Cell-Free Fetal DNA 12.12. China Cell-Free DNA Testing Market Forecast, By Platforms 12.12.1. NGS 12.12.2. RPCR & multiplexed PCR 12.12.3. QPCR & dPCR 12.12.4. Other platform 12.13. China Cell-Free DNA Testing Market Forecast, By Applications 12.13.1. Oncology 12.13.2. NIPT 12.13.3. Gynecology 12.13.4. Transplantation 12.13.5. Other Disease Conditions 12.14. India Cell-Free DNA Testing Market Forecast, By Products 12.14.1. Donor-Derived Cell-Free DNA (DdcfDNA) 12.14.2. Circulating Cell-Free Tumor DNA (CtDNA) 12.14.3. Cell-Free Fetal DNA 12.15. India Cell-Free DNA Testing Market Forecast, By Platforms 12.15.1. NGS 12.15.2. RPCR & multiplexed PCR 12.15.3. QPCR & dPCR 12.15.4. Other platform 12.16. India Cell-Free DNA Testing Market Forecast, By Applications 12.16.1. Oncology 12.16.2. NIPT 12.16.3. Gynecology 12.16.4. Transplantation 12.16.5. Other Disease Conditions 12.17. Japan Cell-Free DNA Testing Market Forecast, By Products 12.17.1. Donor-Derived Cell-Free DNA (DdcfDNA) 12.17.2. Circulating Cell-Free Tumor DNA (CtDNA) 12.17.3. Cell-Free Fetal DNA 12.18. Japan Cell-Free DNA Testing Market Forecast, By Platforms 12.18.1. NGS 12.18.2. RPCR & multiplexed PCR 12.18.3. QPCR & dPCR 12.18.4. Other platform 12.19. Japan Cell-Free DNA Testing Market Forecast, By Applications 12.19.1. Oncology 12.19.2. NIPT 12.19.3. Gynecology 12.19.4. Transplantation 12.19.5. Other Disease Conditions 12.20. ASEAN Cell-Free DNA Testing Market Forecast, By Products 12.20.1. Donor-Derived Cell-Free DNA (DdcfDNA) 12.20.2. Circulating Cell-Free Tumor DNA (CtDNA) 12.20.3. Cell-Free Fetal DNA 12.21. ASEAN Cell-Free DNA Testing Market Forecast, By Platforms 12.21.1. NGS 12.21.2. RPCR & multiplexed PCR 12.21.3. QPCR & dPCR 12.21.4. Other platform 12.22. ASEAN Cell-Free DNA Testing Market Forecast, By Applications 12.22.1. Oncology 12.22.2. NIPT 12.22.3. Gynecology 12.22.4. Transplantation 12.22.5. Other Disease Conditions 12.23. Rest of Asia Pacific Cell-Free DNA Testing Market Forecast, By Products 12.23.1. Donor-Derived Cell-Free DNA (DdcfDNA) 12.23.2. Circulating Cell-Free Tumor DNA (CtDNA) 12.23.3. Cell-Free Fetal DNA 12.24. Rest of Asia Pacific Cell-Free DNA Testing Market Forecast, By Platforms 12.24.1. NGS 12.24.2. RPCR & multiplexed PCR 12.24.3. QPCR & dPCR 12.24.4. Other platform 12.25. Rest of Asia Pacific Cell-Free DNA Testing Market Forecast, By Applications 12.25.1. Oncology 12.25.2. NIPT 12.25.3. Gynecology 12.25.4. Transplantation 12.25.5. Other Disease Conditions 12.26. Asia Pacific Cell-Free DNA Testing Market Attractiveness Analysis 12.26.1. By Products 12.26.2. By Platforms 12.26.3. By Applications 12.27. PEST Analysis 12.28. Key Trends 12.28.1. Key Developments 13. Middle East & Africa Cell-Free DNA Testing Market Analysis 13.1. Middle East & Africa Cell-Free DNA Testing Market Overview 13.2. Middle East & Africa Cell-Free DNA Testing Market Value Share Analysis, By Products 13.3. Middle East & Africa Cell-Free DNA Testing Market Forecast, By Products 13.3.1. Donor-Derived Cell-Free DNA (DdcfDNA) 13.3.2. Circulating Cell-Free Tumor DNA (CtDNA) 13.3.3. Cell-Free Fetal DNA 13.4. Middle East & Africa Cell-Free DNA Testing Market Value Share Analysis, By Platforms 13.5. Middle East & Africa Cell-Free DNA Testing Market Forecast, By Platforms 13.5.1. NGS 13.5.2. RPCR & multiplexed PCR 13.5.3. QPCR & dPCR 13.5.4. Other platform 13.6. Middle East & Africa Cell-Free DNA Testing Market Value Share Analysis, By Applications 13.7. Middle East & Africa Cell-Free DNA Testing Market Forecast, By Applications 13.7.1. Oncology 13.7.2. NIPT 13.7.3. Gynecology 13.7.4. Transplantation 13.7.5. Other Disease Conditions 13.8. Middle East & Africa Cell-Free DNA Testing Market Forecast, by Country 13.8.1. GCC 13.8.2. South Africa 13.8.3. Rest of Middle East & Africa 13.9. Middle East & Africa Cell-Free DNA Testing Market Analysis, by Country/ Sub-region 13.10. GCC Cell-Free DNA Testing Market Forecast, By Products 13.10.1. Donor-Derived Cell-Free DNA (DdcfDNA) 13.10.2. Circulating Cell-Free Tumor DNA (CtDNA) 13.10.3. Cell-Free Fetal DNA 13.11. GCC Cell-Free DNA Testing Market Forecast, By Platforms 13.11.1. NGS 13.11.2. RPCR & multiplexed PCR 13.11.3. QPCR & dPCR 13.11.4. Other platform 13.12. GCC Cell-Free DNA Testing Market Forecast, By Applications 13.12.1. Oncology 13.12.2. NIPT 13.12.3. Gynecology 13.12.4. Transplantation 13.12.5. Other Disease Conditions 13.13. Others South Africa Cell-Free DNA Testing Market Forecast, By Products 13.13.1. Donor-Derived Cell-Free DNA (DdcfDNA) 13.13.2. Circulating Cell-Free Tumor DNA (CtDNA) 13.13.3. Cell-Free Fetal DNA 13.14. South Africa Cell-Free DNA Testing Market Forecast, By Platforms 13.14.1. NGS 13.14.2. RPCR & multiplexed PCR 13.14.3. QPCR & dPCR 13.14.4. Other technology 13.15. South Africa Cell-Free DNA Testing Market Forecast, By Applications 13.15.1. Oncology 13.15.2. NIPT 13.15.3. Gynecology 13.15.4. Transplantation 13.15.5. Other Disease Conditions 13.16. Rest of Middle East & Africa Cell-Free DNA Testing Market Forecast, By Products 13.16.1. Donor-Derived Cell-Free DNA (DdcfDNA) 13.16.2. Circulating Cell-Free Tumor DNA (CtDNA) 13.16.3. Cell-Free Fetal DNA 13.17. Rest of Middle East & Africa Cell-Free DNA Testing Market Forecast, By Platforms 13.17.1. NGS 13.17.2. RPCR & multiplexed PCR 13.17.3. QPCR & dPCR 13.17.4. Other platform 13.18. Rest of Middle East & Africa Cell-Free DNA Testing Market Forecast, By Applications 13.18.1. Oncology 13.18.2. NIPT 13.18.3. Gynecology 13.18.4. Transplantation 13.18.5. Other Disease Conditions 13.19. Middle East & Africa Cell-Free DNA Testing Market Attractiveness Analysis 13.19.1. By Products 13.19.2. By Platforms 13.19.3. By Applications 13.20. PEST Analysis 13.21. Key Trends 13.21.1. Key Developments 14. South America Cell-Free DNA Testing Market Analysis 14.1. South America Cell-Free DNA Testing Market Overview 14.2. South America Cell-Free DNA Testing Market Value Share Analysis, By Products 14.3. South America Cell-Free DNA Testing Market Forecast, By Products 14.3.1. Donor-Derived Cell-Free DNA (DdcfDNA) 14.3.2. Circulating Cell-Free Tumor DNA (CtDNA) 14.3.3. Cell-Free Fetal DNA 14.4. South America Cell-Free DNA Testing Market Value Share Analysis, By Platforms 14.5. South America Cell-Free DNA Testing Market Forecast, By Platforms 14.5.1. NGS 14.5.2. RPCR & multiplexed PCR 14.5.3. QPCR & dPCR 14.5.4. Other platform 14.6. South America Cell-Free DNA Testing Market Value Share Analysis, By Applications 14.7. South America Cell-Free DNA Testing Market Forecast, By Applications 14.7.1. Oncology 14.7.2. NIPT 14.7.3. Gynecology 14.7.4. Transplantation 14.7.5. Other Disease Conditions 14.8. South America Cell-Free DNA Testing Market Value Share Analysis, by Country 14.9. South America Cell-Free DNA Testing Market Forecast, by Country 14.9.1. Brazil 14.9.2. Mexico 14.9.3. Rest of South America 14.10. South America Cell-Free DNA Testing Market Analysis, by Country/ Sub-region 14.11. Brazil Cell-Free DNA Testing Market Forecast, By Products 14.11.1. Donor-Derived Cell-Free DNA (DdcfDNA) 14.11.2. Circulating Cell-Free Tumor DNA (CtDNA) 14.11.3. Cell-Free Fetal DNA 14.12. Brazil Cell-Free DNA Testing Market Forecast, By Platforms 14.12.1. NGS 14.12.2. RPCR & multiplexed PCR 14.12.3. QPCR & dPCR 14.12.4. Other platform 14.13. Brazil Cell-Free DNA Testing Market Forecast, By Applications 14.13.1. Oncology 14.13.2. NIPT 14.13.3. Gynecology 14.13.4. Transplantation 14.13.5. Other Disease Conditions 14.14. Mexico Cell-Free DNA Testing Market Forecast, By Products 14.14.1. Donor-Derived Cell-Free DNA (DdcfDNA) 14.14.2. Circulating Cell-Free Tumor DNA (CtDNA) 14.14.3. Cell-Free Fetal DNA 14.15. Mexico Cell-Free DNA Testing Market Forecast, By Platforms 14.15.1. NGS 14.15.2. RPCR & multiplexed PCR 14.15.3. QPCR & dPCR 14.15.4. Other platform 14.16. Mexico Cell-Free DNA Testing Market Forecast, By Applications 14.16.1. Oncology 14.16.2. NIPT 14.16.3. Gynecology 14.16.4. Transplantation 14.16.5. Other Disease Conditions 14.17. Rest of South America Cell-Free DNA Testing Market Forecast, By Products 14.17.1. Donor-Derived Cell-Free DNA (DdcfDNA) 14.17.2. Circulating Cell-Free Tumor DNA (CtDNA) 14.17.3. Cell-Free Fetal DNA 14.18. Rest of South America Cell-Free DNA Testing Market Forecast, By Platforms 14.18.1. NGS 14.18.2. RPCR & multiplexed PCR 14.18.3. QPCR & dPCR 14.18.4. Other platform 14.19. Rest of South America Cell-Free DNA Testing Market Forecast, By Applications 14.19.1. Oncology 14.19.2. NIPT 14.19.3. Gynecology 14.19.4. Transplantation 14.19.5. Other Disease Conditions 14.20. South America Cell-Free DNA Testing Market Attractiveness Analysis 14.20.1. By Products 14.20.2. By Platforms 14.20.3. By Applications 14.21. PEST Analysis 14.22. Key Trends 14.22.1. Key Developments 15. Company Landscape 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.3. Competitive Benchmarking of Company and Services 15.4. Company Profiles: Key Players 15.4.1. Berry Genomics Co. Ltd 15.4.1.1. Company Overview 15.4.1.2. Financial Overview 15.4.1.3. Business Strategy 15.4.1.4. Recent Developments 15.4.1.5. Development Footprint 15.4.2. Bgi 15.4.3. Biocartis 15.4.4. Biocept, Inc. 15.4.5. Biodesix, Inc. 15.4.6. Boreal Genomics 15.4.7. Caredx, Inc. 15.4.8. Chronix Biomedical 15.4.9. Circulogene Theranostics 15.4.10. Counsyl, Inc. 15.4.11. Cynvenio Biosystems Inc 15.4.12. Exact Sciences 15.4.13. Foundation Medicine 15.4.14. Gatc Biotech 15.4.15. Guardant Health, Inc 15.4.16. Illumina, Inc. 15.4.17. Inivata Limited 15.4.18. Laboratory Corp. Of America Holdings 15.4.19. Lifecodexx Ag 15.4.20. Molecular Md 15.4.21. Multiplicom Nv 15.4.22. Natera, Inc. 15.4.23. Neo New Oncology Ag 15.4.24. Neogenomics Laboratories 15.4.25. Pathway Genomics 15.4.26. Personal Genome Diagnostics 15.4.27. Predicine Holdings Ltd. 15.4.28. Premaitha Health Plc 15.4.29. Prenatalis 15.4.30. Quest Diagnostics 15.4.31. Roche Holdings Ag 15.4.32. Sequenom, Inc. 15.4.33. Sysmex Inostics 15.4.34. Tai Diagnostics, Inc. 15.4.35. The Chinese University Of Hong Kong 15.4.36. Transgenomic, Inc. 15.4.37. Trovagene, Inc. 16. Primary Key Insights
